Cancer cells cause Mayhem in your Genetic Code

By LUIS MIRANDA | THE REAL AGENDA | MARCH 4, 2013

Scientists from Cancer Research UK and the Cancer Institute at the University College of London, have discovered that cancer literally creates chaos in the genetic code which is what allows it to multiply. The finding was published in the Journal Nature.

Most human body cells have 46 chromosomes but, instead, some cancer cells may have more than 100 chromosomes. This fact, however, is inconsistent when analyzed as a group of cells of the same region, as each may have a different chromosome count.

This diversity is what allows tumors to adapt to be intractable and can colonize other parts of the body, as the authors have explained to the BBC.

During an investigation to try to find answers to the diversification of the types of cancer, they found that in the case of colon cancer there is “little evidence” that when a cancer cell divides to create new cells the chromosomes are divided equally.

As explained by Charles Swanton, one of the authors of the study, it was observed that the problem originated in the copies of the genetic code of cancer. Cancers are encouraged to make copies of themselves. But when cancer cells deplete their own raw material or DNA, they developed what it is called “DNA replication stress.”

In this sense, the study showed that this stress leads them to make mistakes and diversification of tumors. “It’s like building a building without bricks or concrete enough at its foundation,” said Swanton. “However, if you can supply raw material DNA, it is possible to reduce stress on diversification to limit the duplication of tumors, which can be therapeutic,” he added.

The expert admitted that “it seems simply incorrect” to provide fuel for therapeutic cancer to grow, but that their observations are that such supply may limit the way and quickness with which cancer spreads.

Swanton notes that this technique has proven that the problem was about replication stress and that the finding can help provide news ideas as to how to attack the cancer.

In addition, Swanton and his team identified three genes that are normally lost in the diversification of intestinal cancer cells, which was critical for cancer suffering from stress in DNA replication.

All cells were located in a region of chromosome 18. This region, as explained by Nic Jones from Cancer Research UK, is “lost” in many cancers, “suggesting that this process is not unique to colon cancer.”

“Scientists can now start looking for ways to prevent this disorder from occurring or turning that instability into a factor that fights the cancer.”

The Real Agenda encourages the sharing of its original content ONLY through the tools provided at the bottom of every article. Please DON’T copy articles from The Real Agenda and redistribute by email or post to the web.

Researchers Develop Technique to ‘predict’ Breast Cancer Metastasis

By LUIS MIRANDA | THE REAL AGENDA | OCTOBER 18, 2012

It is called Raman Microspectroscopy, and it allows researchers to identify the metastatic phenotype of cancer cells from according to their lipid profile.

Researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) and the Institute of Photonic Sciences (ICFO) developed this tool to diagnose and identify how cancer cells multiply in women breast. The creation of this technique is an attempt to learn more about how breast cancer spreads and to try to predict its behavior.

As reported by both research centers, the “Raman microspectroscopy ‘, is a promising technique for identifying metastatic phenotype of breast cancer cells from their lipid profile.

The analysis is based on the characterization of the lipid component of the cells, which according to researchers is indicative of malignancy. This allowed the development of a classifications system for determining the ability of cells to metastasize.

The success of the research, funded by the Instituto de Salud Carlos III, Ministry of Science and Innovation and the Cellex Foundation of Barcelona was published in the online version of the scientific journal PLoS ONE. The achievement seems to have come from the technological development of Raman spectroscopy and the versatility of experimental models of breast cancer.

According to the researchers, the results of this process form the basis for introducing this technique in routine cytological diagnosis, which could be extended in the future to the diagnosis of other tumors.

Researchers analyzed main components to assess the different profile of the lipid composition of the breast cancer cells and generate a classification model of metastatic cells versus the non-metastatic ones.

The study coordinator, Angels from the IDIBELL group, explained that “the algorithm to discriminate metastatic capacity is a first step towards the stratification of breast cancer cells using this tool, which is labeled as fast and non-reactive. ”

Researchers say that cytology studies helped them find a correlation between the activation of lipogenesis (the chemical reaction leading to fatty acids in an organism) and the amount of saturated fats in metastatic cells that indicate a worse prognosis and decreased survival.

The lipid content of the breast cancer cells might be a useful measure to determine various functions coupled to the progression of breast cancer.

The Real Agenda encourages the sharing of its original content ONLY through the tools provided at the bottom of every article. Please DON’T copy articles from The Real Agenda and redistribute by email or post to the web.

Radiation creates Cancer Cells 30 Times More Potent than Regular Cancer Cells

By TONY ISAACS | NATURAL NEWS.COM | MARCH 19, 2012

In a groundbreaking new study just published in the peer reviewed journal Stem Cells, researchers at UCLA’s Johnsson Comprehensive Cancer Center Department of Oncology found that, despite killing half of all tumor cells per treatment, radiation treatments on breast cancer transforms other cancer cells into cancer stem cells which are vastly more treatment-resistant than normal cancer cells. The new study is yet another blow to the failed and favored mainstream treatment paradigm of trying to cut out, poison out or burn out cancer symptoms (tumors) instead of actually curing cancer.

Senior study author Dr. Frank Pajonk, associate professor of radiation oncology at the Jonsson Center, reported that induced breast cancer stem cells (iBCSC) “were generated by radiation-induced activation of the same cellular pathways used to reprogram normal cells into induced pluripotent stem cells (iPS) in regenerative medicine.” Pjonk, who is also a scientist with the Eli and Edythe Broad Center of Regenerative Medicine at UCLA, added “It was remarkable that these breast cancers used the same reprogramming pathways to fight back against the radiation treatment.”

In the new study, Pajonk and his team irradiated normal non-stem cell cancer cells and placed them into mice. Through a unique imaging system, the researchers observed the cells differentiate into iBCSC in response to radiation treatments. Pjonk reported that the newly generated cells were remarkably similar to non-irradiated breast cancer stem cells. The team of researchers also found that the radiation-induced stem cells had a more than 30-fold increased ability to form tumors compared with non-irradiated breast cancer cells.

Despite mounting evidence, mainstream medicine clings to surgery, chemo and radiation and ignores natural solutions

Despite all the billions of dollars spent on cancer, the 40 year “war on cancer” has been a losing one by any honest evaluation. One hundred years ago, anywhere from 1 in 50 to perhaps 1 in 100 people could be expected to develop cancer. Now it is estimated that 1 in every 2 men and 1 in every 3 women will be diagnosed with cancer in their lifetimes. Despite more people around the world developing cancer and dying from cancer every year, mainstream medicine continues to cling to failed treatments which more often than not fail to eliminate the cancer and help cancer spread and return more aggressively than ever. Notably, two of the three major mainstream cancer treatments – radiation and chemo – are themselves highly carcinogenic.

One might think that the new study provided ample reasons to rethink using radiation. However, the study authors looked at the results as an opportunity to continue and enhance the use of radiation by finding ways to control the cell differentiation. What the scientists failed to note is that natural alternatives have already been found which prevent the development of cancer stem cells.

As just one example, Natural News reported in May 2010 that a University of Michigan study had found a compound in broccoli and broccoli sprouts which had the ability to target cancer stem cells. See:
http://www.naturalnews.com/028822_broccoli_breast_cancer.html

The researchers failed to note how cancer cells fought against unnatural treatments. They also failed to take into account the mounting evidence that the best way to beat cancer as well as avoid it is to build and enhance our natural first line of defense – our immune system.

The safest and most effective way to enhance the natural immune system and fight cancer in general is by working with nature. It is also by far the least expensive way, and therein likely lies the rub. You can’t patent and profit from nature like you can with mainstream drugs and treatments.

Note: Neither NaturalNews nor this author condone the inhumane use of animals in medical studies.

Other sources included:

www.cancer.ucla.edu/Index.aspx?page=644
www.sciencedaily.com/releases/2012/02/120213185115.htm
www.naturalnews.com/cancer_cells.html
www.naturalnews.com/stem_cells.html

Chip Detects Cancer Cells in Trial Blood Tests

Study to follow men to see if cancer comes back.  Test may also assess efficacy of targeted drugs

Reuters

Researchers have found a way to test blood for the cells that spread cancer and said they might be able to use the method to predict whose cancer will come back after treatment.

The team at Harvard Medical School and Massachusetts General Hospital used a grant from a non-profit group to develop the test, which they tried out on samples from 20 men with prostate cancer.

They found circulating tumor cells in patients with tumors that had not spread, low-grade cancers and in patients who had their prostate glands taken out three months before.

“These are patient groups in whom we would normally not expect to see circulating tumor cells, so it gives us a tremendous amount of information about their risk,” said Harvard’s Sunitha Nagrath, who led the study.

“Are these patients more prone to come back with recurring disease?” she asked a news conference at a meeting of the American Association for Cancer Research. She said her team would follow the patients to see if the tumors came back in patients who had the circulating cancer cells.

Such a test may also some day serve as a blood test for prostate cancer in addition to PSA or prostate specific antigen tests, which look for a protein made only by prostate cells and which can indicate cancer.

Nagrath said her team’s test can detect 200 circulating tumor cells from a teaspoon of blood taken from a cancer patient.

Prostate cancer is the leading cancer killer of men after lung cancer. But it is often a slow-growing disease and doctors are unsure which men have the most deadly types and which men are most likely to have their cancer spread or come back.

The researchers looked for the circulating tumor cells in the blood one day and nine days after the men had their prostates removed, and then again more than three months later.

They found cells in 42 percent of the patients, and in 64 percent of those with advanced prostate cancer.

The cells could not be found right after surgery but reappeared in some of the patients.

Nagrath said it will be important to follow the men to see how well they do and whether those with more of the circulating cells do more poorly.

She also said the test may be useful for monitoring patients on so-called targeted therapies, which affect cancer cells with certain specific genetic mutations.

“With blood tests you can sample the patients every day to see whether the genotype is changing,” she said.

The charity Stand Up To Cancer paid for the trial.  Among some of the founders of the charity are: GlaxoSmithKline, the Annenberg Foundation, Amgen, the Milken Family Foundation, corporations like Mastercard, Phillips, almost 20 television networks, a long list of publishers as well as corporate internet giants.

DNA Exterminating Cancer Cells

Herald Scotland

Scottish scientists have made cancer tumours vanish within 10 days by sending DNA to seek and destroy the cells.DNA killing cancer cells

The system, developed at Strathclyde and Glasgow universities, is being hailed as a breakthrough because it appears to eradicate tumours without causing harmful side-effects. A leading medical journal has described the results so far as remarkable, while Cancer Research UK said they were encouraging.

Dr Christine Dufes, a lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences and leader of the research, said: “The tumours were completely gone within 10 days. It is fantastic. When you talk about 10 days that is the time frame for curing a cold. Imagine if within 10 days you could completely make a tumour disappear.”

Researchers around the world are trying to find ways to use genes as a cancer treatment, but one problem is ensuring they attack the tumour without destroying healthy tissue.

In laboratory experiments the Strathclyde research team used a plasma protein called transferrin, which carries iron through the blood, to deliver the therapeutic DNA to the right spot. Once in situ the DNA produced a protein that attacked the tumour cells.

The findings have been published in the Journal of Controlled Release, with an accompanying comment from editor Professor Kinam Park, of Purdue University, Indiana, saying other attempts to target genes at cancer cells have “seldom shown complete disappearance of tumours”.

The research was initially supported with a grant from charity Tenovus Scotland, which supports the work of young scientists to help their ideas get off the ground.